We do not agree with Dr Wilson that longer follow-up is needed before conclusions can be reached regarding the benefit of treatment of optic neuritis with oral prednisone. To apply the results of the Optic Neuritis Treatment Trial (ONTT) in deciding whether to prescribe oral prednisone for optic neuritis, it is not important to accept as valid the finding that the patients treated with oral prednisone alone had an increased rate of new attacks of optic neuritis. As seen in both our 6-month and 1-year follow-up results,1,2 the visual outcome was no better with treatment with oral prednisone than with a placebo. Thus even without the finding of an increased rate of new attacks of optic neuritis in the prednisonetreated group, our treatment recommendations would be the same. There is no rationale for prescribing oral prednisone alone in standard dosages for initial episodes of acute demyelinative optic
Beck RW. How Much Should We Editorialize?-Reply. Arch Ophthalmol. 1994;112(3):299. doi:10.1001/archopht.1994.01090150028005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: